{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:09:17Z","timestamp":1778314157517,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.schres.2007.11.013","type":"journal-article","created":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T16:03:15Z","timestamp":1200067395000},"page":"324-332","source":"Crossref","is-referenced-by-count":36,"title":["Dysregulation of glutamate carboxypeptidase II in psychiatric disease"],"prefix":"10.1016","volume":"99","author":[{"given":"Tom\u00e1s R.","family":"Guilarte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima A.","family":"Hammoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"McGlothan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian S.","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Foss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan P.","family":"Kozikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"Pomper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2007.11.013_bib1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2174\/1389450054546015","article-title":"The role of newer antiglutamatergic agents as mood-stabilizers in bipolar disorder","volume":"6","author":"Abelli","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.schres.2007.11.013_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hup.279","article-title":"Glutamate and its role in psychiatric illness","volume":"16","author":"Belsham","year":"2001","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.schres.2007.11.013_bib3","unstructured":"Beneyto, M., Kristiansen, L.V., Oni-Orisan, A., McCullumsmith, R.E., Meador-Woodruff, J.H., in press. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology (Electronic Publication ahead of print)."},{"key":"10.1016\/j.schres.2007.11.013_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/sj.npp.1300559","article-title":"NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons","volume":"30","author":"Bergeron","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2007.11.013_bib5","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1471-4159.2006.04253.x","article-title":"Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus","volume":"100","author":"Bergeron","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2007.11.013_bib6","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1176\/ajp.153.12.1554","article-title":"Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging","volume":"153","author":"Bertolino","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/j.1471-4159.1988.tb10593.x","article-title":"Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity","volume":"50","author":"Blakely","year":"1988","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2007.11.013_bib8","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/cercor\/10.11.1078","article-title":"Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited","volume":"10","author":"Callicott","year":"2000","journal-title":"Cereb. Cortex"},{"key":"10.1016\/j.schres.2007.11.013_bib9","doi-asserted-by":"crossref","first-page":"15653","DOI":"10.1073\/pnas.0507901102","article-title":"Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression","volume":"102","author":"Choudary","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.schres.2007.11.013_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuron.2007.04.015","article-title":"Behavioral phenotypes of Disc1 missense mutations in mice","volume":"54","author":"Clapcote","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2007.11.013_bib11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.bcp.2004.07.034","article-title":"The GABA-glutamate connection in schizophrenia: which is the proximate cause?","volume":"68","author":"Coyle","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.schres.2007.11.013_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10571-006-9062-8","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.schres.2007.11.013_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/oxfordjournals.schbul.a006942","article-title":"Proton magnetic resonance spectroscopy (1H MRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex","volume":"28","author":"Delamillieure","year":"2002","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2007.11.013_bib14","series-title":"The human hippocampus: functional anatomy, vascularization and serial sections with MRI","author":"Duvernoy","year":"1998"},{"key":"10.1016\/j.schres.2007.11.013_bib15","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/1078-0432.CCR-04-2690","article-title":"Radiolabeled small molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer","volume":"11","author":"Foss","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.schres.2007.11.013_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.npp.1300304","article-title":"Glutamate carboxypeptidase II gene expression in the human frontal and temporal lobe in schizophrenia","volume":"29","author":"Ghose","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2007.11.013_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neulet.2005.06.015","article-title":"Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography","volume":"387","author":"Guilarte","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2007.11.013_bib18","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1073\/pnas.081071198","article-title":"Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia","volume":"98","author":"Hakak","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.schres.2007.11.013_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-003-1761-y","article-title":"The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications","volume":"174","author":"Harrison","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2007.11.013_bib20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/0304-3940(80)90178-0","article-title":"Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia","volume":"20","author":"Kim","year":"1980","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.schres.2007.11.013_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00239-006-0137-4","article-title":"Molecular evolution of the transferrin receptor\/glutamate carboxypeptidase II family","volume":"64","author":"Lambert","year":"2007","journal-title":"J. Mol. Evol."},{"issue":"Suppl A","key":"10.1016\/j.schres.2007.11.013_bib23","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.clinthera.2005.07.017","article-title":"Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation","volume":"27","author":"Laruelle","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.schres.2007.11.013_bib24","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1152\/jn.2001.85.3.1097","article-title":"beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor","volume":"85","author":"Lea","year":"2001","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.schres.2007.11.013_bib25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nm1478","article-title":"Pathophysiologically based treatment interventions in schizophrenia","volume":"12","author":"Lewis","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.schres.2007.11.013_bib26","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1001\/archpsyc.55.4.346","article-title":"Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia","volume":"55","author":"Lim","year":"1998","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.neuropharm.2003.10.007","article-title":"NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons","volume":"46","author":"Losi","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.schres.2007.11.013_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","article-title":"Study of a new schizophrenomimetic drug; sernyl. AMA","volume":"81","author":"Luby","year":"1959","journal-title":"Arch. Neurol. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib29","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-3565(24)37683-9","article-title":"Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase)","volume":"286","author":"Luthi-Carter","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.schres.2007.11.013_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1017\/S0033291700033171","article-title":"Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia","volume":"25","author":"Maier","year":"1995","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2007.11.013_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000098653","article-title":"No association between dorsolateral prefrontal gray matter deficit and N-acetyl aspartate ratios in schizophrenia","volume":"54","author":"Molina","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.schres.2007.11.013_bib32","first-page":"477","article-title":"The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia","volume":"26","author":"Neale","year":"2005","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.schres.2007.11.013_bib33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0006-3223(02)01742-0","article-title":"N-acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study","volume":"53","author":"Nudmamud","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.pnpbp.2005.04.038","article-title":"Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex","volume":"29","author":"Ohnuma","year":"2005","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib35","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2007.11.013_bib36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1471-4159.2004.02358.x","article-title":"NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR","volume":"89","author":"Olszewski","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2007.11.013_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1162\/153535002320162750","article-title":"11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase)","volume":"1","author":"Pomper","year":"2002","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.schres.2007.11.013_bib38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0006-8993(84)90727-3","article-title":"A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations","volume":"299","author":"Riveros","year":"1984","journal-title":"Brain. Res."},{"key":"10.1016\/j.schres.2007.11.013_bib39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.neuroscience.2006.10.022","article-title":"Expression of glutamate carboxypeptidase II in human brain","volume":"144","author":"Sacha","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.schres.2007.11.013_bib40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2007.03.028","article-title":"Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel (1)H spectroscopy study","volume":"93","author":"Stanley","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2007.11.013_bib41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0920-9964(99)00192-9","article-title":"The stanley foundation brain collection and neuropathology consortium","volume":"44","author":"Torrey","year":"2000","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2007.11.013_bib42","first-page":"HY39","article-title":"Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia","volume":"11","author":"Tsai","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.schres.2007.11.013_bib43","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1001\/archpsyc.1995.03950220039008","article-title":"Abnormal excitatory neurotransmitter metabolism in schizophrenic brains","volume":"52","author":"Tsai","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2007.11.013_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-4159.2005.03041.x","article-title":"Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors","volume":"93","author":"Urazaev","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2007.11.013_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0079-6123(06)58001-X","article-title":"Tissue preparation and banking","volume":"158","author":"Webster","year":"2006","journal-title":"Prog. Brain. Res."},{"issue":"Suppl A","key":"10.1016\/j.schres.2007.11.013_bib46","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.clinthera.2005.07.016","article-title":"Genetic mechanisms of psychosis: in vivo and postmortem genomics","volume":"27","author":"Weinberger","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.schres.2007.11.013_bib47","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd1903","article-title":"NAAG peptidase inhibitors and their potential for diagnosis and therapy","volume":"4","author":"Zhou","year":"2005","journal-title":"Nat. Rev. Drug. Discov."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099640700518X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099640700518X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T15:38:38Z","timestamp":1737819518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099640700518X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":47,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S092099640700518X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2007.11.013","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}